Thorburn D R
The Murdoch Children's Research Institute and Genetic Health Services Victoria, Royal Children's Hospital, and Department of Paediatrics, University of Melbourne, Melbourne, Australia.
J Inherit Metab Dis. 2004;27(3):349-62. doi: 10.1023/B:BOLI.0000031098.41409.55.
Disorders of mitochondrial oxidative phosphorylation (OXPHOS) are renowned for their variability in clinical features and genetic causes. This makes it difficult to determine their true prevalence, but recent studies have documented a minimum birth prevalence of 13.1/100000 or 1/7634 for oxidative phosphorylation disorders with onset at any age. This clearly remains an underestimate but it indicates that oxidative phosphorylation disorders can be regarded as the most common group of inborn errors of metabolism. Pathogenic mutations causing human oxidative phosphorylation disorders have now been identified in more than 30 of the 37 mitochondrial DNA genes and in more than 30 nuclear genes. Most of the nuclear gene defects cause autosomal recessive diseases, but autosomal dominant and X-linked disorders also occur. It is likely that at least another 30, and perhaps over 100, nuclear-encoded oxidative phosphorylation disorders await identification. Oxidative phosphorylation genetics are complex and there appear to be a number of common misconceptions about mitochondrial DNA mutations that may impede optimal investigation and management of patients. In our experience, mitochondrial DNA mutations are not a negligible cause of OXPHOS disorders in children but account for 20-25% of cases. Similarly, a family history suggesting maternal inheritance is the exception rather than the norm for children with mitochondrial DNA mutations, many of whom have de novo mutations. Only some mitochondrial DNA mutations disappear from cultured cells, so deficient enzyme activity in fibroblasts does not imply the presence of a nuclear defect. Finally, it is still widely thought that there are very few reproductive options that can be offered to women at risk of transmitting a mitochondrial DNA mutation. While a cautious approach is needed, there is now a consensus that prenatal diagnosis should be offered to some women, particularly those at lower recurrence risk. Preimplantation genetic diagnosis can also be an option.
线粒体氧化磷酸化(OXPHOS)紊乱以其临床特征和遗传病因的多样性而闻名。这使得确定其真实患病率变得困难,但最近的研究记录了任何年龄发病的氧化磷酸化紊乱的最低出生患病率为13.1/100000或1/7634。这显然仍然是一个低估,但它表明氧化磷酸化紊乱可被视为最常见的先天性代谢缺陷组。现已在37个线粒体DNA基因中的30多个以及30多个核基因中鉴定出导致人类氧化磷酸化紊乱的致病突变。大多数核基因缺陷导致常染色体隐性疾病,但也会出现常染色体显性和X连锁疾病。很可能至少还有30种,甚至可能超过100种核编码的氧化磷酸化紊乱有待鉴定。氧化磷酸化遗传学很复杂,对于线粒体DNA突变似乎存在一些常见的误解,这可能会妨碍对患者进行最佳的调查和管理。根据我们的经验,线粒体DNA突变在儿童OXPHOS紊乱中并非可忽略不计的病因,而是占病例的20 - 25%。同样,提示母系遗传的家族史对于有线粒体DNA突变的儿童来说是例外而非常态,他们中的许多人都有新发突变。只有一些线粒体DNA突变会从培养细胞中消失,因此成纤维细胞中酶活性不足并不意味着存在核缺陷。最后,人们仍然普遍认为,对于有传播线粒体DNA突变风险的女性,可供选择的生育方案非常少。虽然需要谨慎对待,但现在已达成共识,应该为一些女性,特别是那些复发风险较低的女性提供产前诊断。胚胎植入前遗传学诊断也可以是一种选择。